{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:36:42Z","timestamp":1791905802020,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtct.2025.01.883","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T14:33:33Z","timestamp":1737210813000},"page":"184.e1-184.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-9233","authenticated-orcid":false,"given":"Shunto","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-2994","authenticated-orcid":false,"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8526","authenticated-orcid":false,"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9315","authenticated-orcid":false,"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6796-5440","authenticated-orcid":false,"given":"Takuto","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Meno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-6497","authenticated-orcid":false,"given":"Nozomu","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-315X","authenticated-orcid":false,"given":"Yukiko","family":"Misaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Gomyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-860X","authenticated-orcid":false,"given":"Machiko","family":"Kusuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-3398","authenticated-orcid":false,"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-4224","authenticated-orcid":false,"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3395","authenticated-orcid":false,"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.01.883_bib0001","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.883_bib0002","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.883_bib0003","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1702805","article-title":"Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan","volume":"27","author":"Kanda","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0004","first-page":"2433","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic","volume":"377","author":"Marty","year":"2017","journal-title":"Cell Transplantat"},{"key":"10.1016\/j.jtct.2025.01.883_bib0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-023-05474-1","article-title":"Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection","volume":"103","author":"Takenaka","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.01.883_bib0006","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","article-title":"Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data","volume":"56","author":"Mori","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0007","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/bloodadvances.2023010735","article-title":"Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis","volume":"8","author":"Toya","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.883_bib0008","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0009","doi-asserted-by":"crossref","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0010","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.bbmt.2020.06.025","article-title":"Impact of preemptive therapy for cytomegalovirus on hospitalizations and cost after hematopoietic stem cell transplantation","volume":"26","author":"Fang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0011","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbmt.2019.11.005","article-title":"Cytomegalovirus in allogeneic hematopoietic transplantation: impact on costs and clinical outcomes using a preemptive strategy","volume":"26","author":"Saullo","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0012","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1002\/jmv.25895","article-title":"Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"92","author":"Peffault De Latour","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jtct.2025.01.883_bib0013","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.bbmt.2018.11.028","article-title":"Clinical and economic impact of cytomegalovirus infection among children undergoing allogeneic hematopoietic cell transplantation","volume":"25","author":"Rastogi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0014","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/13696998.2020.1843321","article-title":"Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong","volume":"23","author":"Chan","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.jtct.2025.01.883_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s41669-023-00398-y","article-title":"Cost effectiveness of letermovir for cytomegalovirus prophylaxis compared with pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients in the United States","volume":"7","author":"Sepassi","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jtct.2025.01.883_bib0016","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/jmv.26462","article-title":"Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective","volume":"93","author":"Alsumali","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.jtct.2025.01.883_bib0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2147\/IDR.S196282","article-title":"Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy","volume":"12","author":"Restelli","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jtct.2025.01.883_bib0018","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0019","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.01.883_bib0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/infdis\/jiab212","article-title":"Cytomegalovirus viral load kinetics predict cytomegalovirus end-organ disease and mortality after hematopoietic cell transplant","volume":"224","author":"Stern","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0021","doi-asserted-by":"crossref","first-page":"e13715","DOI":"10.1111\/tid.13715","article-title":"Association between the kinetics of cytomegalovirus reactivation in terms of the area under the curve of cytomegalovirus antigenemia and non-relapse mortality after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Takeshita","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2009.213","article-title":"Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT","volume":"45","author":"Oshima","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0024","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajh.21087","article-title":"Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level","volume":"83","author":"Oshima","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2025.01.883_bib0025","doi-asserted-by":"crossref","first-page":"e73754","DOI":"10.1371\/journal.pone.0073754","article-title":"Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides","volume":"8","author":"Sakamoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2025.01.883_bib0026","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.01.082","article-title":"Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide","volume":"30","author":"Chorao","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.01.883_bib0028","doi-asserted-by":"crossref","first-page":"683.e681","DOI":"10.1016\/j.jtct.2021.04.024","article-title":"Prediction of cytomegalovirus reactivation by recipient cytomegalovirus-IgG titer before allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Kawamura","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.01.883_bib0029","doi-asserted-by":"crossref","first-page":"213.e211","DOI":"10.1016\/j.jtct.2022.01.011","article-title":"Risk of cytomegalovirus infection with post-transplantation cyclophosphamide in haploidentical and HLA-matched unrelated donor transplantation","volume":"28","author":"Jamy","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.01.883_bib0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.01.883_bib0031","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/bloodadvances.2022008667","article-title":"The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients","volume":"7","author":"Sourisseau","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.883_bib0032","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbmt.2009.02.009","article-title":"Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation","volume":"15","author":"Nakamae","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0033","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.883_bib0034","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.883_bib0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/bloodadvances.2021005885","article-title":"Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease","volume":"6","author":"Akahoshi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.01.883_bib0036","doi-asserted-by":"crossref","first-page":"289.e281","DOI":"10.1016\/j.cmi.2015.11.006","article-title":"Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status","volume":"22","author":"Servais","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jtct.2025.01.883_bib0037","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0038","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/bmt.2009.337","article-title":"A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT","volume":"45","author":"Kanda","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.883_bib0039","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.883_bib0040","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.01.883_bib0041","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672500911X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672500911X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:38:18Z","timestamp":1772325498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672500911X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S266663672500911X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.883","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}